Advanced Enzyme Technologies Ltd Overview
Advanced Enzyme Technologies is India's largest enzyme company and one of the few listed, research-led, vertically integrated enzyme and probiotic manufacturers globally. It develops, ferments, formulates and markets more than 400 proprietary products built from over 68 enzymes and probiotic strains, serving four verticals: human nutrition (its dominant franchise, about 63% of FY2026 revenue), animal nutrition, industrial bio-processing (food and non-food), and specialised contract manufacturing. Its economic engine is the high-value, low-volume niche of therapeutic and nutraceutical enzymes — digestive and proteolytic enzymes, and the anti-inflammatory enzyme serratiopeptidase — sold B2B to supplement brands and pharma formulators in the United States and India, with a nascent B2C brand (Wellfa). FY2026 delivered record revenue of INR 7,458M (+17%), EBITDA of INR 2,291M (31% margin) and PAT of INR 1,736M (+30%), on a fortress balance sheet with net cash of roughly 41% of book equity.
Company's own description. In its Integrated Annual Report 2025-26 (themed "Scaling Innovation, Committed to Sustainability") the company describes itself as a research-driven organisation engaged in the research, development, manufacturing and marketing of proprietary enzyme products and probiotics, with leadership in B2B enzyme supply and specialised enzyme expertise that creates significant entry barriers. It frames its mission through the long-standing tagline "Where ENZYME is Life" and its vision of becoming the leading enzyme-based value provider to consumers and bio-processing industries, using enzymes to replace chemicals and improve process efficiency.
Independent characterisation. AETL is best understood as a specialty biologics ingredient manufacturer rather than an industrial-enzyme commodity supplier. Unlike Novonesis, dsm-firmenich or IFF — which dominate high-volume detergent, starch, ethanol and baking enzymes — AETL earns the bulk of its revenue and nearly all of its excess margin from nutraceutical and pharmaceutical-grade enzymes where regulatory dossiers, strain libraries, formulation know-how and long customer qualification cycles matter more than fermentation scale. The US subsidiary (Advanced Enzymes USA, which includes Specialty Enzymes & Biotechnologies) is the commercial spearhead into the American dietary-supplement market and earned PAT of INR 784M on revenue of INR 2,122M in FY2026 — a net margin near 37% (Annual Report FY2026 subsidiary disclosures).
Business model. Overwhelmingly product sales (B2B ingredients and finished formulations), with small contributions from contract manufacturing services (Specialized Manufacturing vertical: effervescent formats, pharma/nutraceutical CDMO via SciTech Specialities, Saignesh, JC Biotech) and B2C consumer sales (Wellfa). There is no material licensing, subscription or royalty revenue disclosed.
Value-chain position. AETL operates across strain development and enzyme engineering (R&D in India, US and Germany via evoxx), submerged and solid-state fermentation, downstream processing, blending/formulation and, increasingly, finished dosage forms. It sits one or two steps upstream of the consumer: its typical customer is a supplement brand or formulator that buys enzyme blends to market under its own label.
Customer types and end markets.
Concentration. Historically the top 10 customers contributed about 28% of revenue (FY2022, per ICICI Securities result update, Q4 FY22) and the anti-inflammatory enzyme (serratiopeptidase) was the single largest product at about INR 1,039M in FY2022 (same source). Updated product-level concentration for FY2026 is not publicly disclosed.
Strategy
Stated strategy (themes from Annual Report FY2026, Q4 FY26 and Q1 FY27 outlook sections).
-
Scaling innovation: continued R&D investment (INR 246M in FY2026) to expand a 400+ product portfolio; new Nashik R&D centre during FY2027.
-
Deepening human nutrition, including B2C: expand the Wellfa brand in India through a dedicated subsidiary (Advanced Nutrazyme), while strengthening US nutrition sales infrastructure.
-
Building Bio-Processing into a key growth engine: the Q1 FY27 outlook describes Bio-Processing as expected to become a key growth driver, with food enzymes a particular focus.
-
Animal nutrition expansion: product development to improve feed efficacy and expand in Asian markets.
-
Inorganic growth: management remains open to strategic acquisitions to strengthen global footprint (Q4 FY26 commentary).
-
Sustainability: "Committed to Sustainability" — enzyme-led replacement of chemical processes, BRSR reporting, renewable-energy participation (SPV).
Strategic initiatives, last 24 months.
Management guidance (medium term). For FY2027, management guided to double-digit revenue growth with EBITDA margins recovering to the historical ~30% level after Q1's 27% (Q1 FY27 call, 12 August 2026). No formal multi-year targets (e.g., 2030 revenue) have been published. Track record caution: FY2025 guidance of 12–14% growth was missed (actual 2%), while FY2026 outperformed (17%).
Products & Services
The company states a portfolio of over 400 proprietary products developed from more than 68 enzymes and probiotics (Annual Report FY2026; company profile). It does not publish SKU-level revenue, pricing or launch dates; where those attributes are absent below they are "not publicly disclosed". Specific trade names are listed only where confirmed in public sources.
Human Nutrition
| Product line | Description / capabilities | Target customer | Launch / version | Pricing model | Flagship / notes |
|---|---|---|---|---|---|
| Digestive enzyme blends | Multi-enzyme formulations (proteases, amylases, lipases, cellulases, lactase, alpha-galactosidase etc.) with activity across gastric pH ranges | US/Indian supplement brands, formulators | — | B2B per-kg/contract | Core of US franchise via Specialty Enzymes & Biotechnologies |
| Proteolytic / systemic enzymes | Protease blends for systemic use (inflammation, recovery) | Supplement brands, pharma | — | B2B | — |
| Serratiopeptidase (anti-inflammatory enzyme) | Proteolytic enzyme sold as API/ingredient for anti-inflammatory formulations | Indian and export pharma formulators | Long-established | B2B | Largest single product historically: ~INR 1,039M in FY2022 (ICICI Securities) |
| Pharmaceutical-grade enzymes (other) | Enzymes for pancreatic-insufficiency and digestive-therapy formulations | Pharma companies | — | B2B | Includes JC Biotech output |
| Probiotics | Bacillus and other strains for gut health, sold as ingredients and in blends | Supplement brands | — | B2B | Shared strain platform with animal probiotics |
| Protein-digestion / sports nutrition enzymes | Enzymes improving protein absorption in sports-nutrition products | Sports-nutrition brands | — | B2B | — |
| Wellfa consumer range (India) | Daily-nutrition supplements: Wellfa Ashwagandha+, Wellfa Digesti-Pro, Wellfa GutStrong, Wellfa Immunoseb (named top sellers) | Indian consumers via D2C site, marketplaces, pharmacy chains | Launched ~FY2024; retail expansion Apr 2024 | MRP retail | Moving into Advanced Nutrazyme Pvt Ltd; FY2025 revenue target INR 100M (outcome not disclosed) |
Animal Nutrition
| Product line | Description / capabilities | Target customer | Launch | Pricing | Notes |
|---|---|---|---|---|---|
| Phytase | Releases bound phosphorus in feed, reducing inorganic phosphate supplementation | Poultry, swine, aqua feed millers | — | B2B per tonne of feed treated | Commodity-like, price competitive |
| NSP enzymes (xylanase, beta-glucanase, cellulase) | Break down non-starch polysaccharides, improve energy availability | Feed millers, integrators | — | B2B | — |
| Multi-enzyme feed blends | Combination products tailored to diet type | Integrators | — | B2B | — |
| Animal probiotics / gut-health products | Direct-fed microbials for performance and gut health | Poultry/aqua producers | — | B2B | Strong Asia growth cited for FY2026 (Q4 FY26 commentary) |
| ABAT agro/animal products | Products marketed by 60%-owned Advanced Bio-Agro Tech | Domestic channel | — | B2B/B2B2C | FY2026 revenue INR 556M |
Industrial Bio-Processing
| Product line | Description / capabilities | Target customer | Notes |
|---|---|---|---|
| Baking enzymes | Amylases, xylanases, lipases for dough conditioning, shelf life | Bakeries, flour millers | Food sub-segment |
| Dairy enzymes | Lactase and processing enzymes | Dairy processors | Food sub-segment |
| Brewing & beverage enzymes | Mashing, clarification, juice-processing enzymes (pectinases) | Breweries, juice processors | Food business grew 18% in Q2 FY26 (Q2 FY26 release) |
| Protein-processing enzymes | Protein hydrolysis for food ingredients | Food ingredient makers | Food sub-segment |
| Textile enzymes | Desizing, bio-polishing, bio-scouring | Textile processors | Non-Food |
| Detergent, paper & pulp, leather enzymes | Process enzymes replacing chemicals | Industrial processors | Non-Food (FY2024 Non-Food ~INR 776M) |
| Grain processing / biofuel enzymes | Starch liquefaction/saccharification | Distilleries, ethanol producers | Non-Food |
| Biocatalysis & specialty carbohydrates (evoxx) | Tailor-made enzymes for chemical synthesis; oligosaccharides/polysaccharides for food | Chemical/pharma, food | evoxx FY2026 revenue INR 319M, PAT INR 50M |
Specialized Manufacturing
| Service | Description | Customers | Notes |
|---|---|---|---|
| Effervescent CDMO | Effervescent granules and tablets for pharma, nutraceutical and animal health; WHO-cGMP, FSSAI approvals (at acquisition) | Third-party brands | SciTech Specialities |
| Pharma / nutra contract manufacturing | Formulation manufacturing | Third-party brands | Saignesh (FY2026 revenue INR 157M, PAT INR 22M) |
| Enzyme contract manufacturing | Fermentation capacity for third parties | Brand owners | — |
Financial Narrative
Income statement
Sources: FY2022 revenue/EBITDA/EPS — ICICI Securities result update Q4 FY22 (EBITDA INR 201.4 crore; ICICI PAT INR 119.6 crore vs. company-reported net profit INR 1,238M incl. minority — discrepancy noted); FY2023–FY2024 — company Q4 FY24 press release; FY2025–FY2026 — Q4 FY26 release, Annual Report FY2026 (EBITDA 2,291 vs 1,944; PAT 1,736 vs 1,340; basic EPS 15.08 vs 11.72). FY2026 DPS = interim INR 4.00 (declared May 2025) + final INR 1.35. FY2025 DPS includes an interim of INR 4.00 (200%, declared May 2024). Gross profit is not reported in a comparable way in sources reviewed; a third-party computed "gross margin" of 34.4% for Q4 FY26 (MarketsMojo) uses a non-standard definition and is not used here.
Margins and growth
Revenue CAGR FY2022–FY2026: 8.9% (analyst calc.). FY2021 revenue was INR 5,018M with EBITDA INR 2,315M (46.1% margin) per ICICI Securities, giving a FY2021–FY2026 revenue CAGR of ~8.3% but an EBITDA CAGR of only ~(-0.2)%: the defining financial fact of the past five years is that revenue compounded while profitability normalised down from the exceptional COVID-era peak.
Commentary. Three regimes are visible. (1) Peak and normalisation (FY2021–FY2023): EBITDA margins fell from ~46% to ~29% as COVID-driven demand for immunity and enzyme supplements faded, raw-material and energy costs spiked, and the high-margin anti-inflammatory enzyme faced pricing pressure (ICICI Securities Q1 FY23 noted raw-material-driven margin contraction). (2) Recovery (FY2024): revenue +15%, EBITDA +32% as costs eased and the US business re-accelerated; however Q4 FY24 PAT was depressed by an exceptional item (PBT after exceptional items fell to INR 397M from INR 589M sequentially, per Q4 FY24 call). (3) Stall then breakout (FY2025–FY2026): FY2025 revenue growth of 2% badly missed the 12–14% guidance as HN fell ~4%; FY2026 delivered the strongest top-line growth in five years (+17%), led by HN recovery (+16%), AN (+25%) and SM (+23%), with domestic sales becoming half the mix. PAT grew faster than EBITDA in FY2026 (+30% vs +18%) helped by lower finance costs and growing treasury income on a rising cash pile (cash and treasury investments up ~19%).
Quarterly trajectory: notes and sources
Sources: quarterly releases and presentations; Q1 FY26 EPS derived from the reported -7% YoY decline to INR 3.31. Quarterly PAT sums to ~1,716 vs reported annual 1,736 (minority/rounding differences between sources). Q1 FY27 PAT was INR 386M total (≈INR 385.9M; attributable ~INR 370M per some aggregators).
Balance sheet
The company confirms zero-debt status and funds expansion from internal accruals (Q4 FY26 commentary).
Working capital (latest). At 30 June 2026, inventory ~INR 1,900M, receivables ~INR 1,310M, payables ~INR 410M (Q1 FY27 call).
Cash flow
The change in net cash (analyst calc. from 6.4) is a robust proxy: the company generated ~INR 1.2 billion of net cash accretion in FY2026 after dividends of ~INR 0.6 billion (interim INR 447.52M + final INR 151.10M declared for FY2026), implying post-capex free cash generation in the region of INR 1.6–1.8 billion before dividends. PP&E grew only ~INR 124M net in FY2026, indicating maintenance-level net capex. The FY2027 buyback (up to INR 697M) is the first share repurchase.
Ratios
All ratios analyst calc. FY2026 ROE on average equity is ~11.4%. Operating ROIC is far higher than ROE: stripping out ~INR 7.0 billion of cash and treasury investments from INR 16.3 billion equity leaves ~INR 9.3 billion of operating capital earning roughly INR 1.4–1.5 billion of post-tax operating profit (analyst estimate), i.e., an operating ROIC in the mid-teens. Inventory and receivable days are on revenue (COGS not available); a full cash conversion cycle is therefore not computed. Receivable days drifted up in FY2026 (to ~71), consistent with faster domestic growth and the Q1 FY27 revenue-recognition reversal flagged by management.
Key financial takeaways. (1) AETL's reported ROE (~10–11%) understates business quality because ~43% of equity sits in low-yielding treasury assets; capital allocation, not operations, is the principal drag on returns — which the August 2026 buyback begins, modestly, to address. (2) Margin volatility is high: quarterly EBITDA margins ranged from ~27% to ~33% over the last seven quarters (MarketsMojo), driven by mix (HN vs. SM/BP), input costs and revenue timing. (3) Mix dilution is structural: the fastest-growing verticals (SM, BP, AN) carry lower margins than US-oriented HN, so double-digit growth does not automatically translate into margin expansion.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Business Verticals
| Vertical | What it contains | Representative products/services |
|---|---|---|
Human Nutrition (HN) | Nutraceutical and pharmaceutical enzymes and probiotics, B2B and B2C | Digestive enzyme blends (protease, amylase, lipase, lactase, cellulase etc.), proteolytic/systemic enzymes, serratiopeptidase (anti-inflammatory API), probiotics, Wellfa consumer products |
Animal Nutrition (AN) | Feed enzymes, probiotics and animal-health formulations | Phytase, xylanase, multi-enzyme feed blends, animal probiotics; via AETL and Advanced Bio-Agro Tech (60%) |
Industrial Bio-Processing (BP) | Food and non-food industrial enzymes | Baking, dairy, brewing, juice, protein-processing enzymes (Food); textile, detergent, paper, leather, grain/biofuel enzymes (Non-Food); biocatalysis via evoxx |
Specialized Manufacturing (SM) | Contract and specialised manufacturing | Effervescent granules/tablets (SciTech Specialities), pharma/nutra contract manufacturing (Saignesh, JC Biotech) |
Revenue by Segment
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Human Nutrition revenue (INR Mn) | 4,185 | 4,035 | 4,674 |
Animal Nutrition revenue (INR Mn) | 677 | 757 | 946 |
Industrial Bio-Processing revenue (INR Mn) | 962 | 1,018 | 1,176 |
Specialized Manufacturing revenue (INR Mn) | 415 | 538 | 662 |
Total revenue from operations, reported (INR Mn) | 6,239 | 6,369 | 7,458 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Segment | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Human Nutrition YoY growth (%) | — | -3.6 | 15.8 |
Animal Nutrition YoY growth (%) | -4.5 | 11.8 | 25.0 |
Industrial Bio-Processing YoY growth (%) | — | 5.8 | 15.5 |
Specialized Manufacturing YoY growth (%) | 19.6 | 29.6 | 23.0 |
Human Nutrition share of revenue (%) | 67.1 | 63.4 | 62.7 |
Animal Nutrition share of revenue (%) | 10.9 | 11.9 | 12.7 |
Industrial Bio-Processing share of revenue (%) | 15.4 | 16.0 | 15.8 |
Specialized Manufacturing share of revenue (%) | 6.7 | 8.4 | 8.9 |
Segment Revenue
| Segment | Q1 FY26 | Q4 FY26 | Q1 FY27 | YoY % | QoQ % |
|---|---|---|---|---|---|
Human Nutrition | 1,221 | 1,281 | 1,139 | -7 | -11 |
Animal Nutrition | 260 | 250 | 252 | -3 | 1 |
Industrial Bio-Processing | 236 | 324 | 306 | 30 | -5 |
Specialized Manufacturing | 142 | 180 | 200 | 41 | 11 |
Total | 1,859 | 2,034 | 1,898 | 2 | -7 |
Group Entities
| Entity | Country | Holding | FY2026 revenue (INR Mn) | FY2026 PAT (INR Mn) | Role |
|---|---|---|---|---|---|
Advanced Bio-Agro Tech Ltd (ABAT) | India | 60% | 556 | 66 | Animal nutrition / agro |
Advanced EnzyTech Solutions Ltd (AESL) | India | 100% | 171 | 14 | Industrial enzyme solutions |
Advanced Nutrazyme Pvt Ltd | India | 100% (w.e.f. 4 Jul 2025) | ~0.02 | — | Wellfa B2C vehicle |
JC Biotech Pvt Ltd | India | 95.72% → 100% (residual 4.28% approved 8 Aug 2026) | NA (FY24: 626) | NA (FY24: 18) | Enzyme/pharma manufacturing |
SciTech Specialities Pvt Ltd | India | — | NA (FY24: 418) | NA (FY24: 37) | Effervescent CDMO |
Saignesh Pharmaceuticals (name per filings) | India | Subsidiary | 157 | 22 | Specialised manufacturing |
Advanced Enzymes USA (consolidated) | USA | 100% | 2,122 | 784 | US nutraceutical enzymes hub |
Advanced Supplementary Technologies Corp. | USA | 100% of AE USA | Consolidated in AE USA | — | US operating sub |
Cal-India Foods International (dba Specialty Enzymes & Biotechnologies) | USA | 100% of AE USA | Consolidated in AE USA | — | US manufacturing/marketing |
Enzyme Innovation Inc. | USA | 100% of AE USA | Consolidated in AE USA | — | US marketing |
Advanced Enzymes Europe B.V. | Netherlands | 100% | Consolidated | — | European holding |
evoxx technologies GmbH | Germany | 100% of AE Europe | 319 | 50 | R&D, biocatalysis, food enzymes |
| — | Malaysia | 100% | — | — | Asia presence |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Mn) | 5,294 | 5,406 | 6,239 | 6,369 | 7,458 |
Revenue growth YoY (%) | 5.5 | 2.1 | 15.4 | 2.1 | 17.1 |
EBITDA (INR Mn) | 2,014 | 1,546 | 2,045 | 1,944 | 2,291 |
Depreciation & amortisation (INR Mn) | — | 350 | 353 | — | — |
Operating income / EBIT, derived (INR Mn) | — | 1,196 | 1,692 | — | — |
Finance costs (INR Mn) | — | 24 | 29 | 35 | 26 |
Profit before tax (INR Mn) | — | 1,404 | 1,879 | — | — |
Profit after tax incl. minority (INR Mn) | 1,238 | 1,039 | 1,370 | 1,340 | 1,736 |
Basic EPS (INR) | 10.7 | — | — | 11.72 | 15.08 |
Dividend per share declared for the year (INR) | — | — | — | — | 5.35 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
EBITDA margin (%) | 38.0 | 28.6 | 32.8 | 30.5 | 30.7 |
EBIT margin, derived (%) | — | 22.1 | 27.1 | — | — |
PBT margin (%) | — | 26.0 | 30.1 | — | — |
Net (PAT) margin (%) | 23.4 | 19.2 | 22.0 | 21.0 | 23.3 |
EBITDA growth YoY (%) | -13.0 | -23.2 | 32.3 | -4.9 | 17.9 |
PAT growth YoY (%) | — | -16.1 | 31.9 | -2.2 | 29.6 |
Income Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|
Revenue (INR Mn) | 1,859 | 1,845 | 1,719 | 2,034 | 1,898 |
EBITDA (INR Mn) | 564 | 601 | 494 | 632 | 510 |
EBITDA margin (%) | 30.3 | 32.6 | 28.7 | 31.1 | 26.9 |
PAT (INR Mn) | 404 | 434 | 425 | 453 | 386 |
EPS (INR) | 3.56 | — | 3.79 | 3.84 | 3.31 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and equivalents (INR Mn) | 2,674 | 964 | 1,138 | 942 | 1,088 |
Cash plus short-term and treasury investments (INR Mn) | 3,709 | 4,823 | 5,461 | 5,923 | 7,049 |
Total debt incl. leases, derived (INR Mn) | 347 | 335 | 473 | 394 | 320 |
Net cash (INR Mn) | 3,362 | 4,488 | 4,988 | 5,529 | 6,729 |
Receivables (INR Mn) | 949 | 1,025 | 1,003 | 1,162 | 1,460 |
Inventory (INR Mn) | 1,209 | 1,240 | 1,485 | 1,573 | 1,773 |
Total current assets (INR Mn) | 6,044 | 7,221 | 8,097 | 8,799 | 10,436 |
Property plant and equipment (INR Mn) | 2,718 | 2,888 | 3,073 | 3,146 | 3,270 |
Retained earnings (INR Mn) | 9,022 | 10,062 | 10,834 | 11,570 | 12,684 |
Shareholders net worth (INR Mn) | — | — | — | 14,209 | 16,320 |
Total assets (INR Mn) | — | — | — | — | 18,388 |
Net cash per share (INR) | 30.05 | 40.14 | 44.58 | 49.37 | 60.06 |
Dividends & Capital Returns
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividends declared for year (INR Mn) | — | — | — | — | 599 |
Share buybacks (INR Mn) | 0 | 0 | 0 | 0 | 0 |
Change in net cash (INR Mn) | — | 1,126 | 500 | 541 | 1,200 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on closing equity (%) | — | — | — | 9.4 | 10.6 |
ROA on closing assets (%) | — | — | — | — | 9.4 |
Debt to equity (x) | — | — | — | 0.03 | 0.02 |
Net cash to EBITDA (x) | 1.7 | 2.9 | 2.4 | 2.8 | 2.9 |
EBITDA to finance cost (x) | — | 64 | 71 | 56 | 88 |
Asset turnover (x) | — | — | — | — | 0.41 |
Receivable days on revenue | 65 | 69 | 59 | 67 | 71 |
Inventory days on revenue | 83 | 84 | 87 | 90 | 87 |
Revenue by Region
| Region | Q1 FY24 | Q1 FY25 | Q1 FY26 | Q1 FY27 |
|---|---|---|---|---|
India (INR Mn) | 737 | 740 | 979 | 937 |
USA (INR Mn) | 467 | 591 | 565 | 546 |
Europe (INR Mn) | 66 | 74 | 92 | 132 |
Asia ex-India (INR Mn) | 119 | 111 | 177 | 242 |
Rest of world (INR Mn) | 84 | 29 | 47 | 40 |
Total (INR Mn) | 1,473 | 1,545 | 1,860 | 1,897 |
Revenue by Region (%) and Revenue by Region
| Region | FY2024 | FY2026 |
|---|---|---|
Domestic share of consolidated revenue (%) | — | 50 |
International share of consolidated revenue (%) | — | 50 |
Advanced Enzymes USA consolidated revenue (INR Mn) | 2,128 | 2,122 |
Advanced Enzymes USA PAT (INR Mn) | 616 | 784 |
Region Overview
| Region | Trend (Q1 FY26 → Q1 FY27) | Drivers (company commentary and analyst view) |
|---|---|---|
Asia ex-India | +37% | Animal nutrition demand in Asian markets (cited in FY2026 commentary), BP food enzymes |
Europe | +43% | Bio-processing/food enzyme wins; evoxx biocatalysis; low base |
India | -4% (after +51% in Q4 FY26) | Q4 FY26 surge in pharma/API and HN; Q1 FY27 reversal of ~INR 100M sales on revenue-recognition timing |
USA | -3% | Inflation-hit consumer spending on supplements, US macro uncertainty (Q4 FY26 call); US flat to down for three years in INR terms |
Rest of world | -15% | Small, lumpy |
Valuation Snapshot
| Metric | Value | Date / source |
|---|---|---|
Latest verified close | INR 269.60 | 9 Oct 2026 (Univest) |
52-week high / low | ~INR 420 / ~INR 252 | Aug–Sep 2026 data (Anand Rathi, IIFL) |
1-year return | -14.2% | to 28 Aug 2026 (Anand Rathi) |
3-year return | ~-10.0% | to 28 Aug 2026 (Anand Rathi) |
Since IPO | +~50% vs split-adjusted IPO price of ~INR 179 (INR 896 ÷ 5), excluding dividends | Analyst calc. |
Peak 2026 post-results | ~INR 377 (25 May 2026) | Sharpely |
Share Price
| Metric | Mar2026 | May2026 | Jul2026 | Aug2026 | Oct2026 |
|---|---|---|---|---|---|
Share price (INR) | 272.6 | 376.9 | 311.0 | 297.0 | 269.6 |
Valuation Snapshot by Multiple
| Multiple | Value | Basis |
|---|---|---|
P/E (TTM) | ~18.2x | TTM EPS ~INR 14.83 (FY26 15.08 − Q1FY26 ~3.56 + Q1FY27 3.31) |
P/E (FY2026) | ~17.9x | EPS INR 15.08 |
EV/EBITDA (TTM) | ~10.5x | EV ~INR 23,440M (market cap less net cash INR 6,729M); TTM EBITDA ~INR 2,237M |
EV/Sales (TTM) | ~3.1x | TTM revenue ~INR 7,497M |
P/B | ~1.85x | Net worth INR 16,320M (FY2026) |
Dividend yield | ~2.0% | FY2026 DPS INR 5.35 |
Net cash as % of market cap | ~22% | — |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2025 | FY2026 |
|---|---|---|
Interim dividend per share (INR) | 4.00 | 4.00 |
Final dividend per share (INR) | — | 1.35 |
Total dividend outlay declared (INR Mn) | — | 599 |
Payout ratio of PAT (%) | — | 34.5 |
Analyst Conclusions
Management guidance. FY2027: double-digit revenue growth with EBITDA margin recovering to ~30% (Q1 FY27 call). Q1 FY27 delivered +2% revenue and 27% margin, so the remaining nine months must grow ~13–14% at ~31% margins to hit the guide (analyst calc.).
Consensus expectations. No verifiable institutional consensus. The market-implied view, at ~18x trailing earnings and ~10.5x EV/EBITDA with 22% of the market cap in net cash, embeds low-to-mid single-digit growth — a meaningful discount to management's guide.
Bull case.
-
FY2026 proved the growth algorithm: 17% revenue growth with all four verticals contributing, and Q4 FY26 revenue of INR 2,034M (+22%) shows the capacity to compound at mid-teens when HN cooperates.
-
Optionality in the balance sheet: ~INR 7.0B of cash and investments (≈23% of market cap) funds bolt-on M&A, the INR 697M buyback and dividends without leverage; each INR 1B redeployed at a 15% return adds ~INR 1.1 per share of EPS (analyst calc.).
-
Diversification is working: BP (+30% YoY in Q1 FY27), SM (+41%), Asia (+37%) and Europe (+43%) are reducing reliance on the US, while the US subsidiary remains highly profitable (37% net margin in FY2026).
Bear case.
-
The core is stalling: HN fell 7% and US fell 3% in Q1 FY27; the US subsidiary's revenue has not grown since FY2024 in INR terms.
-
Margin pressure is structural: faster-growing verticals carry lower margins, and management itself has flagged input-cost inflation; EBITDA margin has not exceeded 33% since FY2022.
-
Execution and capital-allocation credibility: FY2025 guidance was missed by ~10 points; ROE has languished at ~9–11% for years because cash was hoarded; the buyback is small relative to cash.
Catalysts and monitorables (next 12 months).
Analyst verdict.
Advanced Enzyme Technologies is a high-quality, under-levered specialty biologics franchise trapped in a low-return capital structure and an uneven growth cadence. The operating business is better than headline returns suggest: an India-cost, US-facing nutraceutical enzyme platform that has sustained EBITDA margins of roughly 29–38% through a full commodity and post-COVID cycle, generates ample cash, and has never needed debt. FY2026 was the cleanest year in half a decade — record revenue, 31% EBITDA margin, 30% PAT growth, and broad-based contribution from animal nutrition, bio-processing and specialised manufacturing.
Yet the equity has de-rated to roughly 18x trailing earnings and about 10.5x EV/EBITDA, with net cash covering more than a fifth of the market value. The market is pricing in the bear case: a stagnant US franchise, mix-driven margin dilution, and management guidance that has proven unreliable. Q1 FY27 reinforced those concerns — human nutrition down 7%, margin at 27%, and a revenue-recognition reversal that invites scrutiny of earnings quality.
The investment debate therefore hinges on two variables. First, can human nutrition — still about 63% of revenue — return to growth, particularly in the US, so that faster-growing but lower-margin verticals add to, rather than dilute, consolidated margin? Second, will the promoter-led board deploy the roughly INR 7 billion of cash and treasury assets into accretive acquisitions or larger capital returns? The INR 697 million buyback is a constructive first signal, but small relative to the cash pile.
On balance, the risk-reward appears asymmetric to the upside for patient investors at current levels, given cash backing, dividend yield near 2% and valuation well below global enzyme peers, but conviction should be conditional on evidence of HN recovery and margin restoration toward 30% in the Q2 and Q3 FY27 prints. Absent that, the stock is likely to remain a value trap rather than a compounder.
Sources (primary and secondary, as cited)
| Source | Type | Used for |
|---|---|---|
| AETL Integrated Annual Report 2025-26 (advancedenzymes.com, Jul 2026) | Primary | FY2026 financials, subsidiaries, R&D, employees, office address |
| AETL Board's Report FY2026 (via IIFL/GoodReturns) | Primary (reproduced) | Subsidiary financials, dividends, ESOP |
| AETL BRSR FY2025 and FY2026 (NSE archive, company site) | Primary | Employees, states served, subsidiaries |
| AETL quarterly earnings releases and presentations Q1 FY24 – Q1 FY27 (NSE/BSE archives, company site) | Primary | Revenue, EBITDA, PAT, segments, geography |
| AETL Q4 FY26 earnings call transcript (12 May 2026; financialfilings.com, AlphaStreet, GuruFocus summary) | Primary (transcript) | Strategy, risks, R&D centre |
| AETL Q1 FY27 earnings call (12 Aug 2026; Quartr, Investywise summaries) | Primary (summarised) | Guidance, working capital, R&D |
| AETL AGM notice FY2026 and AGM outcomes (2025, 2026) | Primary | Board, auditor |
| Corporate governance compliance reports FY2026 (company site) | Primary | Board composition |
| NSE prior intimations (2025–2026) | Primary | Results dates |
| Promoter SAST Reg 31(4) disclosure, Apr 2026 (NSE) | Primary | Promoter group |
| ICICI Securities result updates Q4 FY22, Q1 FY23, Q2 FY23 | Broker research | FY2020–FY2022 financials, product concentration |
| stockanalysis.com balance sheet (NSE:ADVENZYMES) | Aggregator | 5-year balance sheet |
| Trendlyne, Upstox, IIFL, Bajaj Finserv shareholding and deal data | Aggregator | Ownership, bulk/block deals |
| Chittorgarh buyback tracker; Multibagg/ScanX/FilingReader summaries of exchange filings | Aggregator | Buyback terms, filing summaries |
| Anand Rathi, IIFL, Univest, Sharpely, 5paisa, Aaj Tak market data | Aggregator | Share prices, returns |
| Business Standard / Capital Market (Dec 2020) | News | SciTech acquisition |
| CHEManager, BIOÖKONOMIE.DE, HTGF (Aug 2017) | News | evoxx acquisition |
| UNI/PNN Wellfa press release (Apr 2024) | Company PR | Wellfa |
| Novonesis FY2025 annual results release (26 Feb 2026) | Peer primary | Competitive benchmark |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Title | Tenure / background | Education | Notes |
|---|---|---|---|---|
Vasant L. Rathi | Promoter; Chairman, Non-Executive Non-Independent Director | Co-founder; heads US subsidiaries; largest individual shareholder (~26.7%) | — | Board chair role per historic presentations; confirm in latest CG report |
Chandrakumar (Chandrakant) L. Rathi | Promoter; Managing Director | Co-founder, long-time MD | — | Promoter-group disclosures under SAST Reg 31(4), Apr 2026 |
Mukund M. Kabra | Whole-Time Director | Senior executive since pre-IPO; re-appointed for 5 years from 1 Apr 2027 (AGM 31 Jul 2026) | MBA (SCMHRD) per historic presentation (verify) | Leads earnings calls |
Savita C. Rathi | Whole-Time Director (historic) | Promoter group | — | — |
Beni Prasad Rauka | Group Chief Financial Officer | Joined 2000 as consultant; long-serving CFO | — | Q1 FY27 call participant |
Sanjay Basantani | Company Secretary and Head – Legal | — | — | Signatory on exchange filings |
Piyush C. Rathi | Senior management (Advanced Enzymes USA / Asia business) | Promoter group | — | — |
Rasika Rathi | Senior management (Advanced Enzymes USA; evoxx business development historically) | Promoter group | — | — |
Ronak Saraf | Investor Relations Manager | — | — | Q1 FY27 call |
Governance Overview
| Governance item | Status |
|---|---|
Independence | 5 of 9 directors independent (majority) |
Chair/CEO separation | Yes — non-executive promoter chair; promoter MD as executive head (family control persists) |
Committees | Audit, Nomination & Remuneration, Stakeholders' Relationship, CSR, Risk Management (per Listing Regulations); audit committee of 4 with 3 independents |
Secretarial compliance FY2026 | Clean annual secretarial compliance report; no regulatory actions against promoters/directors |
Promoter pledge | Nil (promoter Reg 31(4) declaration, Apr 2026) |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
9 May 2026 | Board recommends appointment of Pradip B. Shah (independent) and re-appointment of Mukund Kabra | Board refresh / continuity |
12 Jun 2026 | Pradip B. Shah joins as additional independent director | — |
31 Jul 2026 | AGM approves Shah, Kabra and MSKA re-appointment | All resolutions passed |
Shareholding Trend
| Holder category | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
Promoter and promoter group (%) | 43.08 | 43.08 | 43.04 | 43.25 | 43.23 |
Foreign portfolio investors (%) | 11.90 | 23.46 | 25.86 | 25.50 | 26.70 |
Mutual funds (%) | 5.36 | 5.46 | 2.16 | — | — |
Other domestic institutions (%) | 2.83 | 2.99 | 3.35 | — | — |
Retail and others (%) | 36.83 | 25.02 | 25.59 | 25.83 | 25.26 |
Major Shareholders
| Holder | Type | Stake (%) | Source / date |
|---|---|---|---|
Vasant Rathi | Promoter (foreign) | 26.69 | Bajaj Finserv data, Jun 2026 |
Rasika Vasant Rathi | Promoter group | 2.38 | Same |
Reshma Namita Rathi | Promoter group | 2.36 | Same |
Rachana Vasant Rathi | Promoter group | 2.36 | Same |
Kishor Laxminarayan Rathi HUF | Promoter group | 0.98 | Exchange SHP, Jun 2025 |
Prabhavati Vasant Rathi | Promoter group | 0.82 | Bajaj Finserv data |
Madhusudan Kabra | Promoter group | 0.55 | Same |
Vasant and Prabha Rathi Generation Trust | Promoter group | — | Trendlyne, Mar 2026 |
Polunin Emerging Markets Small Cap Fund | FPI | ≥1.1 (1.25M shares bought 29 Aug 2025) | NSE bulk deal |
Motilal Oswal entity (block buyer, Jun 2024) | Domestic institution | — | NSE block deal, 19 Jun 2024 |
Competitive Landscape
Key Competitors
| Competitor | HQ | Segments where it competes | Scale / latest metrics | Relative positioning vs AETL |
|---|---|---|---|---|
Novonesis (Novozymes + Chr. Hansen) | Denmark | Food & beverage enzymes, human health (supplements/probiotics), feed (with dsm-firmenich alliance historically), industrial | 2025 organic growth 7%; adjusted EBITDA margin 37.1%; 2026 guide 5–7% growth (company release, Feb 2026). | Global leader; far larger, broader, higher R&D; overlaps AETL in probiotics, food and dietary-supplement enzymes |
dsm-firmenich | Switzerland/Netherlands | Feed enzymes, food enzymes, nutrition ingredients | — | Scale leader in feed/food; competes with AETL AN and BP |
IFF (Health & Biosciences, ex-Genencor/DuPont) | USA | Industrial, food, feed enzymes; probiotics | — | Scale competitor in BP and probiotics |
AB Enzymes (Associated British Foods) | Germany | Baking, food, feed, textile enzymes | — | Strong in baking/textile — direct BP overlap |
Amano Enzyme | Japan | Food and pharmaceutical/nutraceutical enzymes | Private; not disclosed | Closest global peer in specialty digestive/pharma enzymes |
Deerland Probiotics & Enzymes (ADM) | USA | Supplement enzymes and probiotics | Acquired by ADM (2021); not disclosed | Direct US HN competitor |
Kerry Group (enzymes) | Ireland | Food and supplement enzymes, probiotics | — | Competes in food enzymes and supplement ingredients |
BASF (feed enzymes) | Germany | Phytase, NSP feed enzymes | — | AN competitor |
Adisseo | France/China | Feed enzymes and additives | — | AN competitor |
Biocatalysts Ltd (BRAIN Biotech) | UK | Specialty food and biocatalysis enzymes | — | Overlaps evoxx/BP niche |
Indian enzyme makers (e.g., Aumgene Biosciences, Lumis Biotech; unlisted) | India | Industrial, feed, nutraceutical enzymes | Private | Price competition in domestic BP/AN |
Chinese enzyme producers (various) | China | Commodity industrial and feed enzymes, serratiopeptidase | Private | Major price pressure on commodity enzymes and APIs |
Peer Comparison FY2026
| Metric | AETL FY2026 | Novonesis FY2025 |
|---|---|---|
Revenue growth (%) | 17 | 7 |
EBITDA margin (%) | 30.7 | 37.1 |
R&D intensity (% of sales) | 3.3 | — |
Net debt to EBITDA (x) | -2.9 | — |
